Akari Therapeutics plc ADR (0.01 USD) (AKTX)
NASDAQ · Manufacturing · Pharmaceutical preparations
AKTX price, last 12 months
Key stats
- Previous close
- $10.06
- Open
- $10.25
- Day range
- $9.30 – $10.25
- 52-week range
- $3.02 – $49.60
- Volume
- 71.5K
- Avg volume (20 days)
- 89K
- Market cap
- $19.0M
Performance
Technicals and fundamentals
About Akari Therapeutics plc ADR (0.01 USD)
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $19.0M